Opendata, web and dolomites

HEPCAN SIGNED

A Humanized Monoclonal Anti-Claudin1 Antibody (anti-CLDN1 mAb) for Treatment of Hepatocellular Carcinoma (HCC)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HEPCAN project word cloud

Explore the words cloud of the HEPCAN project. It provides you a very rough idea of what is the project "HEPCAN" about.

monotherapy    fibrosis    steatohepatitis    2040    resistance    usually    populations    fibrotic    constrains    trigger    frequent    disease    livers    causes    inappropriate    recommended    recurrence    months    fatty    first    patients    fact    damaging    77    triggers    benefit    iarc    combination    viruses    therapy    primary    molecules    375    closely    leads    efficacy    owing    prognosis    drugs    hepatitis    diagnosis    progression    urgent    poor    tumor    2018    cells    systemic    precision    alcoholism    approved    amounted    screening    compound    resection    keep    liver    prolonging    validate    symptoms    unmet    persistent    reaching    amongst    cancer    accelerate    stages    survival    option    curative    hcc    treatment    alcoholic    consequently    drug    continual    hepatocellular    sub    deaths    cell    suggesting    resistant    worldwide    medical    therapeutic    carcinoma    population    cirrhotic    nature    fda    mortality    absence    sorafenib    medicine    heterogeneity    valuable    80    aggressive    experiencing    rising   

Project "HEPCAN" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

Hepatocellular carcinoma is the most frequent primary liver cancer and owing to its very aggressive nature is amongst the leading cause of cancer mortality worldwide (IARC). The number of liver cancer-related deaths in Europe in 2018 amounted to 77 375, and this number is expected to keep rising, reaching an estimated number of more than 100 000 deaths in 2040 (IARC). Major causes include the hepatitis B and C viruses, alcoholism, Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. All of these medical conditions trigger liver fibrosis by damaging the liver and are closely associated with the development of HCC. As a matter of fact, more than 80% of HCC develop in fibrotic or cirrhotic livers. Early stages of liver cancer do not usually produce symptoms, and many challenges are associated with the screening of HCC, leading to its late diagnosis. The absence of effective drug treatment for HCC makes its resection the first curative option with most of the patients experiencing HCC recurrence within 5 years. All these factors contribute to the poor prognosis of the HCC patients. Sorafenib is the only currently approved systemic therapy for advanced HCC in the EU, only prolonging survival by an average of 3 months, the treatment often leads to drug resistance. Indeed, intra-tumor heterogeneity strongly constrains the therapeutic benefit of precision medicine and triggers drug-resistant sub-population of cells. Consequently, persistent treatment of drug-resistant tumor cells may accelerate tumor progression, suggesting that inappropriate and continual use of a compound on drug-resistant cancer cells is not recommended. Thus, there is an urgent unmet medical need to identify and to validate the therapeutic efficacy of new valuable molecules – i.e. targeting the existing drug-resistant cell populations -that could be used in monotherapy or in combination therapy with FDA-approved drugs to improve HCC treatment responses.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEPCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

FLATBANDS (2020)

Exploring strong correlations in flat bands

Read More  

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More